US$4.083M Revenues for Q3 2023 compared to US$749,000 for Q3 2022, representing an increase of 445% US$3.664M Gross Profit for Q3 2023 compared to USD 715,000...
HERZLIYA, Israel and CALGARY, Alberta, Nov. 3, 2023 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in...
HERZLIYA, Israel and CALGARY, Alberta, Oct. 23, 2023 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”), a pioneer in...
NOT FOR DISSEMINATION IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HERZLIYA, Israel and CALGARY, Alberta, Oct. 20, 2023 /PRNewswire/ — Innocan...
NOT FOR DISSEMINATION IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HERZLIYA, Israel and CALGARY, Alberta, Oct. 12, 2023 /PRNewswire/ — Innocan...
Innocan hair care cream efficacy trial observes enhanced hair growth in male and female participants in a 14day period. 91 % of participants reported stronger hair...
HERZLIYA, Israel and CALGARY, AB, Aug. 29, 2023 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”) is pleased to announce...
US$3.121M Revenues for Q2, 2023 compared to US$415,000 for Q2 2022, representing an increase of 652% US$2.656M Gross Profit for Q2, 2023 compared to USD 214,000...
HERZLIYA, Israel, and CALGARY, Alberta, July 25, 2023 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan“) is pleased to...
HERZLIYA, Israel and CALGARY, AB, June 22, 2023 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF), a leading innovator in pharmaceutical solutions for...